FMP
NeuroSense Therapeutics Ltd.
NRSNW
NASDAQ
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
0.372 USD
-0.0885 (-23.82%)
About
ceo
Mr. Alon Ben-Noon
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
CIK
0001875091
ISIN
IL0011811630
CUSIP
M74240116
Address
Medinat ha-Yehudim Street 85
Phone
972 9 953 1142
Country
IL
Employee
18
IPO Date
N/A
Key Executives
